pt003018 – A Randomized, Double

[PDF]

Study Code PT003018 / FLUI-2015-139 Edition Number 1 Date 27 February 2017 A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD.

This study is inactive. The user who created this study has canceled his edc2go account.

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Furniture and linen; Metal constructions for the building industry; Heating, ventilation, air conditioning (HVAC) and refrigeration equipment; Metal pipework, valves and containers

PT003018/AB: Executive: Infrastructure Management-K007: Executive: Infrastructure Management: ExpatHR: Expat HR Director: EMEA: PS007784/CM: Financial Accountant-PS007601/SJ: Financial Administration / Accounts Clerk – Delmas-DUR001281/KD: Financial Advisor-PE001774/LL: Financial Assistant-PE001728/NV: Financial Controller (Equity)-NFC004549

Clinical Trial Results: A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development. Learn more about the EU Clinical Trials Register including the source of the information and the legal basis.

Deputy Business Executive – Assurance Pretoria Deputy Business executive – Assurance 3 days ago Business Executive Pretoria This role is accountable for the implementation of the client’s strategy to take back major State Owned Companies (SOCs) in the short-term and to set up the necessary structures to ensure that the planned enhanced governance activities are effectiv

[PDF]

2.5 臨床に関する概括評価 一般名:グリコピロニウム臭化物/ホルモテロールフマル酸塩水和物 5 2.5.5.11.2.4 治験薬の投与中止に至った有害事象(pt010007試験[pt010006試

Os dados que recolhemos são apenas os necessários para o uso adequado do nosso serviço. Ao continuar a utilizar os nossos serviços a partir de 25 de maio de 2018, reconhece e concorda com nossa Política de Privacidade e Política de Cookies atualizada.